Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma

Recruiting now · Not applicable

Conditions studied: Hepatocellular Carcinoma, Immunotherapy

In brief

Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors related to the sensitivity of comprehensive treatment. We used the PD-L1 expression level of patients before comprehensive treatment，characteristic morphology of tertiary lymphoid structures, as well as other parameters, are used to construct a liver cancer comprehensive treatment efficacy evaluation model. Using this liver cancer comprehensive treatment efficacy evaluation model, we conducted a randomized controlled trial on whether to receive comprehensive treatment for liver cancer patients to verify the accuracy and practical value of the model.

Key facts

Study ID

NCT06542796

Run by

Second Affiliated Hospital, Zhejiang University, School of Medicine

People needed

100

Starts

2024-09-01

Expected to finish

2027-05-01

Last updated by the study team

2025-02-10

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced hepatocellular carcinoma

You may not qualify if…

• Have comorbidities of severe diabetes, heart failure, liver and/or kidney failure
• Have a history of schizophrenia
• Have a history of other malignant tumors or metastatic liver tumors discovered after surgery
• Received anti-tumor drugs for other diseases
• Special groups such as pregnant and lactating women.

Where it is running

• 2ndAffiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.